InventisBio website screenshot

InventisBio

InventisBio Co., Ltd. (Shanghai Stock Exchange STAR Market: 688382) is a clinical-stage biopharmaceutical company headquartered in the Pudong New Area of Shanghai, China, with operations in New Jersey, United States. Built on independent R&D capabilities, InventisBio discovers and develops innovative small-molecule and targeted therapies for oncology, autoimmune, and metabolic diseases to address unmet medical needs. The company has advanced multiple drug candidates into clinical trials, including late-stage Phase III programs in non-small cell lung cancer and breast cancer, alongside earlier-stage assets targeting KRAS G12C, synthetic-lethal pathways, hyperuricemia/gout, and plaque psoriasis. It was added to the API Evangelist network as a portfolio company of Qiming Venture Partners. InventisBio is a research-driven pharmaceutical company and does not currently publish a public developer API, SDKs, or API documentation.

InventisBio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Autoimmune Disease.

InventisBio’s developer surface includes engineering blog, support, and 2 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyPharmaceuticalsOncologyAutoimmune DiseaseMetabolic DiseaseClinical TrialsDrug DiscoveryChina

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.1/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/inventisbio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Inventisbio Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: inventisbio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/inventisbio.png
name: InventisBio
description: 'InventisBio Co., Ltd. (Shanghai Stock Exchange STAR Market: 688382) is a clinical-stage biopharmaceutical company
  headquartered in the Pudong New Area of Shanghai, China, with operations in New Jersey, United States. Built on independent
  R&D capabilities, InventisBio discovers and develops innovative small-molecule and targeted therapies for oncology, autoimmune,
  and metabolic diseases to address unmet medical needs. The company has advanced multiple drug candidates into clinical trials,
  including late-stage Phase III programs in non-small cell lung cancer and breast cancer, alongside earlier-stage assets
  targeting KRAS G12C, synthetic-lethal pathways, hyperuricemia/gout, and plaque psoriasis. It was added to the API Evangelist
  network as a portfolio company of Qiming Venture Partners. InventisBio is a research-driven pharmaceutical company and does
  not currently publish a public developer API, SDKs, or API documentation.'
url: https://raw.githubusercontent.com/api-evangelist/inventisbio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Autoimmune Disease
- Metabolic Disease
- Clinical Trials
- Drug Discovery
- China
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/inventisbio-domain-security.yml
- type: Website
  url: https://inventisbio.com
- type: Blog
  name: News & Information
  url: https://www.inventisbio.com/en/news-information/
- type: Support
  name: Contact Us
  url: https://www.inventisbio.com/en/contact-us-2/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence